Absci News Today

launched by summit president sultan al—jaber, saying they "clearly fall short of what is required." countries and oil companies at the un climate talks have promised to make major progress in tackling global warming in a large new energy pledge. around 100 countries promised to treble world renewable energy use by 2030. but guterres points out the agreement "says nothing about eliminating emissions "from fossil fuel consumption. " lets fill you in more detail in the comments by the c...

Absci Co. (NASDAQ:ABSI – Free Report) – HC Wainwright increased their FY2025 earnings estimates for shares of Absci in a report released on Monday, January 8th. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings of ($0.23) per share for the year, up from their previous estimate of ($0.30). HC Wainwright […]

Sir Pangalos is a distinguished biopharmaceutical executive who led BioPharmaceuticals R&D at AstraZeneca. In addition to joining Absci’s Board, Sir Pangalos will co-chair Absci’s Scientific Advisory Board. VANCOUVER, Wash., Jan. 10, 2024 (GLOBE NEWSWIRE) -- Absci (Nasdaq: ABSI), a generative AI drug creation company, today announced the appointment of seasoned R&D executive Professor Sir Menelas “Mene” Pangalos to its Board of Directors and as co-chair of A...

The Healthtech Times is a weekly newsletter covering healthtech news from Canada and around the globe.

KeyCorp initiated coverage on shares of Absci (NASDAQ:ABSI – Free Report) in a research note published on Tuesday morning, Marketbeat reports. The firm issued an overweight rating and a $3.00 price target on the stock. KeyCorp also issued estimates for Absci’s Q4 2023 earnings at ($0.22) EPS, FY2023 earnings at ($1.17) EPS and FY2024 earnings […]

Casdin Capital LLC cut its holdings in shares of Absci Co. (NASDAQ:ABSI – Free Report) by 74.6% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,368,260 shares of the company’s stock after selling 4,025,000 shares during the period. Casdin Capital […]

Absci Co. (NASDAQ:ABSI – Get Free Report) was the recipient of a significant decline in short interest during the month of November. As of November 15th, there was short interest totalling 2,300,000 shares, a decline of 6.5% from the October 31st total of 2,460,000 shares. Based on an average daily volume of 323,400 shares, the […]

AstraZeneca taps into AI firms to build cancer antibodies to replace chemotherapy. . Generative AI-Built Cancer Antibodies will reportedly be worked on by AstraZeneca and Absci after signing a deal approximately worth $247 million, as reported by Reuters.

Absci (ABSI) announced a collaboration with AstraZeneca to deliver an AI-designed antibody against an oncology target. Absci will contribute its generative AI technology to deliver a therapeutic candidate antibody for a specified oncology target.

The collaboration aims to harness Absci's AI technology for large-scale protein analysis to find a viable oncology therapy, a leading focus of AstraZeneca, the report said. It did not say what kind of cancer they plan to target.